drug_type
RELEVANT_DRUG
intervention_type
Drug (radiopharmaceutical)
drug_description
Actinium-225–macropa–pelgifatamab (225Ac‑pelgi), a PSMA-targeted radioimmunoconjugate in which the anti‑PSMA monoclonal antibody pelgifatamab is chelated via macropa to the alpha-emitter actinium‑225 to deliver targeted alpha radiation; administered IV every 6 weeks for mCRPC.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Radiopharmaceuticals
drug_category
RADIOIMMUNOCONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
An anti‑PSMA monoclonal antibody (pelgifatamab) is chelated via macropa to the alpha‑emitter actinium‑225. After binding PSMA on prostate cancer cells, the conjugate delivers short‑range, high‑LET alpha radiation that induces lethal DNA double‑strand breaks, leading to targeted tumor cell death.
drug_name
BAY3546828
nct_id_drug_ref
NCT06052306